Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase

Molecular Cancer Research

Volumn 10, Issue 10, 2012, Pages 1306-1318

  Lehman, Heather L ^a,b   Van Laere, Steven J ^d,e   Van Golen, Cynthia M ^c   Vermeulen, Peter B ^e   Dirix, Luc Y ^e   Van Golen, Kenneth L ^a,b  

^a UNIVERSITY OF DELAWARE   (United States)

^b HELEN F GRAHAM CANCER CENTER   (United States)

^c DELAWARE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e Oncology Center   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACID ANHYDRIDE HYDROLASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B ALPHA; PROTEIN KINASE B BETA; PROTEIN KINASE B GAMMA; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; CYTOSKELETON; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATORY BREAST CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; CELL LINE, TUMOR; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 84867647110     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0173     Document Type: Article

References (45)

1. Lee B, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obstet 1924;39:580-95.
2. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-24.
3. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423-9. (Pubitemid 32223639)
4. Woodward WA, Cristofanilli M. Inflammatory breast cancer. Semin Radiat Oncol 2009;19:256-65.
5. Beahrs OH. Staging of cancer. CA Cancer J Clin 1991;41:121-5.
6. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, et al. Identifying factors that impact survival among women with inflammatory breast cancer. Annal Oncol 2011;23:870-5.
7. Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2003;55:1200-8. (Pubitemid 36338285)
8. Lerebours F, Bieche I, Lidereau R. Update on inflammatory breast cancer. Breast Cancer Res 2005;7:52-8. (Pubitemid 40352670)
9. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, et al. Trends for inflammatory breast cancer: is survival improving? Oncologist 2007;12:904-12. (Pubitemid 47359132)
10. Alpaugh ML, Tomlinson JS, Ye Y, Barsky SH. Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol 2002;161:619-28. (Pubitemid 36142170)
11. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999;5:2511-9. (Pubitemid 29437336)
12. Van den Eynden GG, Van dAI, Van LS, Colpaert CG, van DP, Merajver S, et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 2004;85:13-22.
13. Kjoller L, Hall A. Signaling to Rho GTPases. Exp Cell Res 1999;253:166-79.
14. Sahai E, Marshall CJ. RHO-GTPases and Cancer. Nat Rev 2002;2:133-42.
15. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol 2001;11:471-7. (Pubitemid 33079138)
16. Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001;114:2713-22. (Pubitemid 32785451)
17. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000;2:418-25. (Pubitemid 32044787)
18. Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, et al. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998;77:147-52. (Pubitemid 28029787)
19. Ikoma T, Takahashi T, Nagano S, Li YM, Ohno Y, Ando K, et al. A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin Cancer Res 2004;10:1192-200. (Pubitemid 38198921)
20. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406:532-5. (Pubitemid 30625739)
21. Testa JR, Bellacosa A. Akt plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 2001;98:10983-95.
22. Manning BD, Cantley LC. Akt/PKB signaling: navigating downstream. Cell 2007;129:1261-74. (Pubitemid 46962095)
23. Sun M. Akt1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001;159:431-4.
24. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005;171:1023-33.
25. Ethier SP, Kokeny KE, Ridings JW, Dilts CA. ErbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Cancer Res 1996;56:899-907. (Pubitemid 26055484)
26. Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 2005;93:237-46. (Pubitemid 41441293)
27. Van Laere S, Van der Auwera I, Van den Eynden G, Van Hummelen P, van Dam P, Van Marck E, et al. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer 2007;97:1165-74. (Pubitemid 47586999)
28. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000;60:5832-8.
29. Van Laere S, Van den Eynden GG, Van der Auwere I, Vandenberghe M, van Dam P, Van Marck EA, et al. Identification of cell-of-origin breast tumor cell subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006;95:243-55.
30. van Golen KL, Bao LW, Pan Q, Miller FR, Wu ZF, Merajver SD. Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis 2002;19:301-11. (Pubitemid 34606755)
31. Van den Eynden GG, Van Laere S, Van der Auwere I, Merajver S, Van Marck EA, van Dam P, et al. Overexpression of caveolin-1 and -2 in cell lines and human samples of inflammatory breast cancer. Breast Cancer Res Treat 2005;95:219-28.
32. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signaling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
33. Lu Y, Lin Y, LaPushin R, Cuevas B, Fang X, Yu S, et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induced apoptosis and anoikis in breast cancer cells. Oncogene 1999;18:7034-45. (Pubitemid 30028874)
34. Radunsky GS, van Golen KL. The current understanding of the molecular determinants of inflammatory breast cancer metastasis. Clin Exp Metastasis 2005;22:615-20. (Pubitemid 44259522)
35. Kwon T, Kwon DY, Chun J, Kim JH, Kang SS. Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 2000;275:423-8. (Pubitemid 30039001)
36. Unger H, van Golen KL. Akt signaling in oncology. Belgian J Med Oncol 2009;3, 4:139-44.
37. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44. (Pubitemid 47123510)
38. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A 1987;84:5034-37. (Pubitemid 17095859)
39. Staal SP, Hartley JW. Thymic lymphoma induction by the AKT8 murine retrovirus. J Exp Med 1988;167:1259-61.
40. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 2005;20:539-45.
41. Cheng JQ, Goldwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, et al. Akt2, a putative oncogene encoding amember of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992;89:9267-70.
42. Bertucci F, Finetti P, Birnbaum D, Viens P. Gene expression profiling of inflammatory breast cancer. Cancer 2010;116:2783-93.
43. Garcia S, Dales JP, Jacquemier J, Charafe-Jauffret E, Birnbaum D, Andrac-Meyer L, et al. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer 2007;96:329-35. (Pubitemid 46160639)
44. Dias SMG, Cerione RA. X-ray crystal sturctures reveal two actived states for RhoC. Biochemistry 2007;46:6547-58.
45. van Golen KL. RhoC GTPase in Cancer Progression and Metastasis. In:van Golen KL, editor. The Rho GTPases in Cancer. New York: Springer; 2010. p. 123-34.